C4 Therapeutics
CCCC
123 hedge funds and large institutions have $221M invested in C4 Therapeutics in 2026 Q1 according to their latest regulatory filings, with 34 funds opening new positions, 41 increasing their positions, 31 reducing their positions, and 11 closing their positions.
209% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 11
189% more call options, than puts
Call options by funds: $1.02M | Put options by funds: $352K
45% more capital invested
Capital invested by funds: $153M → $221M (+$68.8M)
32% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 31
22% more funds holding
Funds holding: 101 → 123 (+22)
4.2% more ownership
Funds ownership: 82.39% → 86.59% (+4.2%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$7.58M |
| 2 |
SCM
Squadron Capital Management
Westmont,
Illinois
|
+$5.3M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$4.86M |
| 4 |
Two Sigma Investments
New York
|
+$3.59M |
| 5 |
Goldman Sachs
New York
|
+$3.06M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$21.8M |
| 2 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$3.26M |
| 3 |
O
OrbiMed
New York
|
-$1.29M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.15M |
| 5 |
Walleye Capital
New York
|
-$481K |
CCCC Hedge Fund Activity: Q1 2026 in Review
123 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in C4 Therapeutics (CCCC) for Q1 2026, worth a combined $221M — up 45% from $153M a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new CCCC positions and 11 closed out — a net gain of 23 holders — while 41 added to existing stakes and 31 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $7.58M. The largest seller was Point72 Asset Management, cutting an estimated $21.8M.
- 123 institutional investors held C4 Therapeutics (CCCC) as of Q1 2026, up from 101 in Q4 2025.
- Funds reported $221M of C4 Therapeutics stock for Q1 2026, up 45% quarter-over-quarter.
- 34 funds opened new C4 Therapeutics positions in Q1 2026 and 11 closed out, a net change of +23 holders.
- The largest C4 Therapeutics buyer in Q1 2026 was JP Morgan Chase, an estimated $7.58M added.
- The largest C4 Therapeutics seller in Q1 2026 was Point72 Asset Management, an estimated $21.8M sold.
Based on aggregated 13F filings for Q1 2026.